GSK (GSK) Expected to Announce Quarterly Earnings on Wednesday
by Doug Wharley · The Cerbat GemGSK (NYSE:GSK – Get Free Report) will likely be posting its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect GSK to post earnings of $1.18 per share and revenue of $10.4220 billion for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 7:00 AM ET.
GSK Trading Down 2.1%
Shares of GSK stock opened at $56.12 on Wednesday. The company has a fifty day simple moving average of $56.57 and a 200-day simple moving average of $51.21. GSK has a 12-month low of $35.45 and a 12-month high of $61.69. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.92. The stock has a market cap of $113.88 billion, a price-to-earnings ratio of 15.17, a PEG ratio of 3.37 and a beta of 0.46.
GSK Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, April 9th. Stockholders of record on Friday, February 20th were issued a $0.4856 dividend. This represents a $1.94 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, February 20th. This is a positive change from GSK’s previous quarterly dividend of $0.42. GSK’s dividend payout ratio (DPR) is currently 50.81%.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. Citigroup restated a “neutral” rating on shares of GSK in a report on Monday, February 9th. Weiss Ratings cut shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 19th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research note on Friday, January 16th. Barclays reiterated an “underweight” rating on shares of GSK in a research note on Friday, February 20th. Finally, TD Cowen reiterated a “hold” rating on shares of GSK in a research note on Monday, February 9th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, GSK has a consensus rating of “Reduce” and a consensus target price of $53.00.
Read Our Latest Analysis on GSK
Institutional Trading of GSK
A number of large investors have recently bought and sold shares of the business. Align Financial LLC bought a new position in shares of GSK during the fourth quarter valued at $5,628,000. Arkadios Wealth Advisors lifted its holdings in shares of GSK by 59.0% during the fourth quarter. Arkadios Wealth Advisors now owns 107,379 shares of the pharmaceutical company’s stock valued at $5,266,000 after acquiring an additional 39,863 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of GSK by 28.2% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after acquiring an additional 26,685 shares during the period. AQR Capital Management LLC lifted its holdings in shares of GSK by 84.4% during the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock valued at $1,559,000 after acquiring an additional 18,420 shares during the period. Finally, Brighton Jones LLC bought a new position in shares of GSK during the fourth quarter valued at $528,000. Institutional investors and hedge funds own 15.74% of the company’s stock.
GSK Company Profile
GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.
GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.